Altimmune’s lead asset, pemvidutide/ALT-801, falls squarely in that trend, combining the potent weight-loss effects of GLP-1 with glucagon’s direct liver-targeted lipid metabolism, the firm adds.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback